BOLTBolt Biotherapeutics, Inc.

Nasdaq boltbio.com


$ 1.29 $ -0.01 (-0.75 %)    

Tuesday, 14-May-2024 15:59:08 EDT
QQQ $ 445.88 $ 1.10 (0.25 %)
DIA $ 395.58 $ 1.12 (0.28 %)
SPY $ 523.16 $ 2.25 (0.43 %)
TLT $ 90.86 $ 0.51 (0.56 %)
GLD $ 218.12 $ 1.83 (0.85 %)
$ 1.32
$ 1.29
$ 0.00 x 0
$ 0.00 x 0
$ 1.28 - $ 1.32
$ 0.84 - $ 2.03
101,397
na
50.25M
$ 0.96
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 05-14-2024 03-31-2024 10-Q
2 03-21-2024 12-31-2023 10-K
3 11-09-2023 09-30-2023 10-Q
4 08-07-2023 06-30-2023 10-Q
5 05-11-2023 03-31-2023 10-Q
6 03-29-2023 12-31-2022 10-K
7 11-10-2022 09-30-2022 10-Q
8 08-10-2022 06-30-2022 10-Q
9 05-12-2022 03-31-2022 10-Q
10 03-30-2022 12-31-2021 10-K
11 11-09-2021 09-30-2021 10-Q
12 08-12-2021 06-30-2021 10-Q
13 05-13-2021 03-31-2021 10-Q
14 03-31-2021 12-31-2020 10-K
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 bolt-biotherapeutics-q1-2024-gaap-eps-028-beats-049-estimate-sales-530m-beat-206m-estimate

Bolt Biotherapeutics (NASDAQ:BOLT) reported quarterly losses of $(0.28) per share which beat the analyst consensus estimate of ...

 hc-wainwright--co-maintains-buy-on-bolt-biotherapeutics-maintains-8-price-target

HC Wainwright & Co. analyst Edward White maintains Bolt Biotherapeutics (NASDAQ:BOLT) with a Buy and maintains $8 price ...

 bolt-biotherapeutics-q4-eps-047-beats-048-estimate-sales-209m-beat-171m-estimate

Bolt Biotherapeutics (NASDAQ:BOLT) reported quarterly losses of $(0.47) per share which beat the analyst consensus estimate of ...

 bolt-biotherapeutics-enrolls-first-patient-in-phase-2-clinical-study-evaluating-bdc-1001-in-patients-with-her2-positive-breast-cancer-previously-treated-with-enhertu

Bolt Biotherapeutics, Inc. (NASDAQ:BOLT), a clinical-stage biopharmaceutical company developing novel immunotherapies for the t...

 bolt-biotherapeutics-q3-eps-043-beats-050-estimate-sales-253m-beat-172m-estimate

Bolt Biotherapeutics (NASDAQ:BOLT) reported quarterly losses of $(0.43) per share which beat the analyst consensus estimate of ...

 bolt-biotherapeutics-presents-updated-clinical-data-from-phase-1-dose-escalation-trial-of-bdc-1001-as-monotherapy-and-in-combination-with-nivolumab-in-her2-expressing-tumors-at-esmo-2023-congress

Updated safety data supports the selection of 20 mg/kg q2w as the recommended Phase 2 dose (RP2D) Improved efficacy with one pa...

 why-aerwins-technologies-shares-are-trading-higher-by-around-90-here-are-20-stocks-moving-premarket

Gainers AERWINS Technologies Inc. (NASDAQ: AWIN) shares rose 90.2% to $0.2297 in pre-market trading. Aerwins Technologies i...

 stocks-that-hit-52-week-lows-on-friday

  Friday's session saw 112 companies set new 52-week lows.

 stocks-that-hit-52-week-lows-on-thursday

  During Thursday's session, 406 companies made new 52-week lows.

Core News & Articles

BNOX: 700% | Bionomics Announces Positive Topline Results from the Phase 2b ATTUNE Clinical Trial of BNC210 in Patients with Po...

 stocks-that-hit-52-week-lows-on-tuesday

  On Tuesday, 210 companies reached new 52-week lows.

 hc-wainwright--co-reiterates-buy-on-bolt-biotherapeutics-maintains-8-price-target

HC Wainwright & Co. analyst Edward White reiterates Bolt Biotherapeutics (NASDAQ:BOLT) with a Buy and maintains $8 price...

 bolt-biotherapeutics-q2-eps-048-up-from-061-yoy-sales-143m-up-from-139m-yoy

Bolt Biotherapeutics (NASDAQ:BOLT) reported quarterly losses of $(0.48) per share. This is a 21.31 percent increase over losses...

 hc-wainwright--co-reiterates-buy-on-bolt-biotherapeutics-maintains-8-price-target

HC Wainwright & Co. analyst Edward White reiterates Bolt Biotherapeutics (NASDAQ:BOLT) with a Buy and maintains $8 price...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION